Amendments to the Claims

The listing of claims will replace all prior versions, and listing of claims in the application.

Listing of Claims

Claims 1-12. Canceled without prejudice.

- affective disorder which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a bupropion metabolite, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, wherein the affective disorder is alcohol addiction, an anxiety disorder, attention deficit disorder, a bipolar or manic condition, bulimia, chronic fatigue syndrome, narcolepsy, seasonal affective disorder, premenstrual syndrome, or weightgain.
- 14. (Original) The method of claim 13 wherein the bupropion metabolite is optically pure.
- 15. (Currently Amended) The method of claim 14 wherein the optically pure bupropion metabolite is optically pure (S,S)-2-(3-chlorophenyl)-2-hydroxy-3,5,5-trimethyl-morphinol hydroxybupropion.
 - Claim 16-19. Canceled without prejudice.
 - Claims 20-38. Previously canceled without prejudice.
 - Claims 39-57. Canceled without prejudice.
- 58. (New) The method of claim 14 wherein the optically pure bupropion metabolite is (R,R)-2-(3-chlorophenyl)-2-hydroxy-3,5,5-trimethyl-morphinol; (S,S)-2-(3-chlorophenyl)-2-hydroxy-3,5,5-trimethyl-morphinol; (R,R)-2-(*tert*-butylamino)-1-(3-chlorophenyl)-propan-1-ol; (S,R)-2-(*tert*-butylamino)-1-(3-chlorophenyl)-propan-1-ol; (S,S)-2-(*tert*-butylamino)-1-(3-chlorophenyl)-propan-1-ol;

(R,S)-2-(*tert*-butylamino)-1-(3-chlorophenyl)-propan-1-ol; (R)-1-(3-chlorophenyl)-2-[(1,1-dimethylethanol)amino]-1-propanone; or (R)-1-(3-chlorophenyl)-2-[(1,1-dimethylethanol)amino]-1-propanone.

- 59. (New) The method of claim 13 wherein adverse effects associated with the administration of racemic bupropion are reduced or avoided.
- 60. (New) A method of treating or preventing nicotine addiction which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of (S,S)-2-(3-chlorophenyl)-2-hydroxy-3,5,5-trimethyl-morphinol, or a pharmaceutically acceptable salt, solvate, or clathrate thereof.